Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Theratechnologies Inc
T.TH
Alternate Symbol(s):
THTX
Healthcare
Biotechnology
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs...
in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSX:TH)
New Post
View:
Posts & Comments
Threaded Posts
Prev
...
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
...
Next
(107)
•••
Trogarzon
X
View Profile
View Bullboard History
Comment by
Trogarzon
on May 28, 2024 8:55am
RE:Market does know how to value biotech companies. See below
Just saying the market got it wrong with Thera in 2010, 2014 and 2018... by a mile. Taling 20 cents to 15$ wrong.
(17)
•••
Momo25
X
View Profile
View Bullboard History
Post by
Momo25
on May 27, 2024 11:56pm
Market does know how to value biotech companies. See below
The Best Biotech Stocks of May 2024 Company (TICKER) 5-Year Average Annual EPS Forecast
...more
Pharmaceutical Tech Co Reports 2.7X Revenue Growth Year-Over-Year at US $24 Million
posted Nov 21, 2024 9:00am by
Innocan Pharma Corp
-
|
"Our strong operational and financial momentum continued throughout 2024 and now in the third quarter, we again demonstrated solid financial results. We are pleased to report nine consecutive quarters of continuous revenue growth. Our online platform continues to perform exceptionally well, contributing to our strong nine-month revenue growth of 174% YoY ...read more
(56)
•••
Mannequin
X
View Profile
View Bullboard History
Comment by
Mannequin
on May 27, 2024 6:31pm
RE:RE:ASCO Info
I had my contact at GSK put a recent phase two result through my AI model this AM and it said it was not good enough to move forward - and that is the case in their phase 2 example. So it's pretty
...more
(51)
•••
Qwerty54321
X
View Profile
View Bullboard History
Comment by
Qwerty54321
on May 27, 2024 5:27pm
RE:ASCO Info
One thing the AI didn't pick up is the analysis is for a SUBSET of all treated patient. I'm not going to go back and check the PR but it's something like 3 "women's" cancers,
...more
(107)
•••
Trogarzon
X
View Profile
View Bullboard History
Comment by
Trogarzon
on May 27, 2024 2:51pm
RE:It's about trust
In the mean time the market as you call it with all it's mighty intelligencia (the market is always wright the saying goes) buys Trump media and Gamestop. Apart from our dear management
...more
(17)
•••
Momo25
X
View Profile
View Bullboard History
Post by
Momo25
on May 27, 2024 2:46pm
It's about trust
Th management and the CEO have overwhelmigly lied in the past so nobody trust them anymore. Hence, whatever the results might be of interest they are not making the market moving to the right
...more
(56)
•••
Mannequin
X
View Profile
View Bullboard History
Post by
Mannequin
on May 27, 2024 8:09am
AI Conclusion of Abstract
### Interpretation and Considerations 1. **Efficacy:** - The stabilization of disease in a heavily pretreated population, along with a partial response and complete response
...more
(56)
•••
Mannequin
X
View Profile
View Bullboard History
Post by
Mannequin
on May 27, 2024 8:04am
ASCO Info
I let the most advanced AI that I have access to review several ASCO abstracts from other companies. It concluded that these other companies were not really getting the results necessary in the
...more
(56)
•••
Mannequin
X
View Profile
View Bullboard History
Comment by
Mannequin
on May 26, 2024 2:26pm
RE:RE:RE:RE:RE:RE:RE:New Press Release - Theratechnologies' Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors
It is sad it potentially could have helped, and I wonder if anyone else in her situation has been put through the program with ovarian cancer and seen any benefit. There is not much explained thus far
...more
(41)
•••
juniper88
X
View Profile
View Bullboard History
Comment by
juniper88
on May 26, 2024 11:45am
RE:RE:RE:RE:RE:RE:New Press Release - Theratechnologies' Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors
The biomarker for ovarian cancer is CA-125. With my wife after 1 infusion of TH1902 it dropped by over 40%. I remember Dr. Winers assistant coming back to us with a smile. We were very
...more
(17)
•••
Momo25
X
View Profile
View Bullboard History
Comment by
Momo25
on May 26, 2024 12:22am
RE:RE:RE:RE:RE:RE:RE:RE:New Press Release - Theratechnologies' Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors
To JFM3030, I wish full recovery. Just keep fighting this beast as much as you can!
(43)
•••
SPCEO1
X
View Profile
View Bullboard History
Comment by
SPCEO1
on May 25, 2024 6:59pm
RE:RE:RE:RE:RE:RE:RE:RE:New Press Release - Theratechnologies' Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors
I don't know if I really feel like I recovered asI felt fine before getting my stents, the procedure placing the stents was a breeze and I have felt fine ever since. The only improvement I have
...more
(78)
•••
jfm1330
X
View Profile
View Bullboard History
Comment by
jfm1330
on May 25, 2024 1:29pm
RE:RE:RE:RE:RE:RE:RE:New Press Release - Theratechnologies' Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors
Thanks for your good words and thoughts SPCEO. I hope you are recovering well from your own health problems.
(43)
•••
SPCEO1
X
View Profile
View Bullboard History
Comment by
SPCEO1
on May 25, 2024 12:53pm
RE:RE:RE:RE:RE:RE:New Press Release - Theratechnologies' Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors
I am glad there are other treatment options for you but sad to hear of your declining quality of life. You have battled this beast for a very long time and I am sure it takes an emotional as well as
...more
Prev
...
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >